Table 3

Kinetic parameters for CYP3A4 substrates showing sigmoidicity

Substrate	Pathway	V_max	S₅₀	n	H factor	CL_max	S_max	Reference, System
		min⁻¹	μM			μl/min/pmol CYP	μM
Aflatoxin B1	3-hydroxylation	8.1	43	2.4	0.51	0.096	50	Ueng et al., 1997, E. coli
Aflatoxin B1	3-hydroxylation	1	27	3.6	0.55	0.021	35	Ueng et al., 1997, RFP
Aflatoxin B1	8,9-epoxidation	0.9	27	4.1	0.57	0.019	36	Ueng et al., 1997, E. coli
Aflatoxin B1	8,9-epoxidation	0.1	33	3.8	0.56	0.002	43	Ueng et al., 1997, RFP
Amitriptyline	N-demethylation	9	490	1.5	0.53	0.010	309	Shaw et al., 1997, RFP
Amitriptyline	N-demethylation	12	330	1.4	0.55	0.020	172	Ueng et al., 1997, E. coli
Carbamazepine	10,11-epoxidation	13	221	1.48	0.53	0.031	135	Korzekwa et al., 1998, VV
Diazepam	3-hydroxylation	30	140	1.42	0.54	0.12	76	Kenworthy, 1999, β-LM
Diazepam	N-demethylation	2.7	152	1.20	0.64	0.011	40	Kenworthy, 1999, β-LM
Estradiol	2-hydroxylation	3.7	13	1.3	0.58	0.166	5.1	Ueng et al., 1997, β-LM
Nifedipine	Oxidation	35	37	1.4	0.55	0.52	19	Shaw et al., 1997, RFP
Nifedipine	Oxidation	45	14	2	0.50	1.61	14	Shaw et al., 1997, BV
Progesterone	6β-hydroxylation	46	32	1.1	0.74	1.06	4	Ueng et al., 1997, β-LM
Testosterone	6β-hydroxylation	19	51	1.45	0.54	0.20	29	Kenworthy, 1999, β-LM
Testosterone	6β-hydroxylation	150	25	1.7	0.51	3.05	20	Shaw et al., 1997, BV
Testosterone	6β-hydroxylation	54	160	1.3	0.58	0.20	63	Ueng et al., 1997, E. coli